177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Conditions:   Neuroendocrine Tumors;   Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Gastroenteropancreatic Neuroendocrine Tumor;   Vipoma;   Insulinoma;   Gastrinoma Intervention:   Drug: 177Lu-DOTATOC Sponsor:   British Columbia Cancer Agency Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials